Raymond James Financial
MRNA icon

Raymond James Financial’s Moderna MRNA Stock Holding History

Raymond James Financial’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.95M Sell
142,082
-55,137
-28% -$2.85M ﹤0.01% 2163
2026
Q1 		$10M Buy
197,219
+88,616
+82% +$4.13M ﹤0.01% 2019
2025
Q4 		$3.2M Buy
108,603
+7,524
+7% +$204K ﹤0.01% 2879
2025
Q3 		$2.61M Buy
101,079
+16,011
+19% +$447K ﹤0.01% 2961
2025
Q2 		$2.35M Sell
85,068
-18,429
-18% -$485K ﹤0.01% 2949
2025
Q1 		$2.93M Sell
103,497
-100,752
-49% -$3.58M ﹤0.01% 2706
2024
Q4 		$8.49M Buy
+204,249
New +$9.76M ﹤0.01% 1954

Other funds holding MRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return

Raymond James Financial's MRNA Position: Q2 2026 in Review

Raymond James Financial reduced its Moderna (MRNA) stake by 28% in Q2 2026, selling an estimated $2.85M and leaving 142,082 shares worth $9.95M. The position accounts for ﹤0.01% of the portfolio, ranked #2163.

Raymond James Financial first reported a position in MRNA in Q4 2024 and has held it in 7 quarters since. The position peaked at $10M in Q1 2026. 783 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

  • Raymond James Financial held 142,082 shares of Moderna worth $9.95M as of Q2 2026.
  • Raymond James Financial sold 55,137 Moderna shares in Q2 2026, an estimated $2.85M.
  • Moderna made up ﹤0.01% of Raymond James Financial's portfolio in Q2 2026, its #2163 holding.
  • Raymond James Financial first reported a position in Moderna in Q4 2024 and has held it in 7 quarters since.
  • Raymond James Financial's Moderna position peaked at $10M in Q1 2026.
  • 783 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on Raymond James Financial's 13F filing for Q2 2026, filed 14 Aug 2026.